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age was 53.3 ± 11.21 years, educated till secondary level (39.4%), Malays (44.2%) 
and married for 27.73 ± 12.12 years. Life expectancy gained from vaccination is 13.04 
years and average Quality Adjusted Life-years saved (QALYs) is 24.40 in vaccinated 
versus 6.29 in unvaccinated women. Cost/QALYs saved for Pap smear at base case is 
RM 1214.96/QALYs and RM 1100.01/QALYs at increased screening coverage. In 
HPV vaccination, base case is at RM 35,346.79/QALYs and RM 46,530.08/QALYs 
when vaccination price is increased. In combined strategy, cost/QALYs at base case 
is RM 11,289.58/QALYs; RM 7712.74/QALYs at best case and RM 14,590.37/
QALYs at worst case scenario. Incremental cost-effectiveness ratio (ICER) showed 
that screening at 70% coverage or higher is highly cost effective at RM 946.74 per 
QALYs saved and this is followed by combined strategy at RM 35,346.67 per QALYs 
saved. Budget impact analysis indicated that it cost the government RM 180.4 million 
per year and 2.5% of the national health budget. CONCLUSIONS: Vaccination 
increase life expectancy with better QOL. Cost effective strategies will include increas-
ing the Pap smear coverage to 70% or higher. Since feasibility and long term screening 
adherence is doubtful among Malaysian women; vaccination of young women is more 
cost effective strategy against cervical cancer. 
PIH8
ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT 
HPV TYPES 6, 11, 16, 18 VACCINE IN THAILAND USING A 
TRANSMISSION DYNAMIC MODEL
Singhal PK1, Termrungruanglert W2, Khemapech N2, Havanond P2, Taneepanichskul S2
1Merck & Co., Inc., West Point, PA, USA; 2Chulalongkorn University, Bangkok, Thailand
OBJECTIVES: The quadrivalent (6,11,16,18) HPV vaccine has been approved in 
Thailand for prevention of cervical cancer, vulvar/vaginal pre-cancers, and genital 
warts in women age 9 to 26 years. To assess the health and economic impact of the 
quadrivalent (6,11,16,18) HPV vaccine in Thailand. METHODS: A published math-
ematical model of the transmission dynamics of HPV infection and disease was 
adapted for Thailand. Model inputs were used from Thailand or the Asia/Paciﬁ c 
region when available; otherwise, the default values in the original model were used. 
Maintaining current cervical cancer screening practices in Thailand, we evaluated two 
strategies: routine vaccination of females by age 12 (S1), and S1 combined with a 
temporary (5 years) female catch-up program for age 12–24 years (S2). The vaccine 
coverage rates were 70% for the routine and 50% for the catch-up vaccination pro-
grams. The perspective of analysis was health-care system. RESULTS: The most 
effective strategy was S2. Using this strategy over 100 years in the population of 
Thailand, the estimated cumulative percent reduction in incident HPV 6/11/16/18-
related genital warts-female, genital warts-male, cervical intraepithelial neoplasia 
(CIN) grade 1, CIN 2/3, and cervical cancer cases was 72%, 55%, 61%, 63%, and 
48%, respectively. The cost-effectiveness ratios were Thai Baht 145,447 or US$4,453 
(weakly dominated), and Thai Baht 131,845 or US$4,036 per quality-adjusted life-
years (QALY) gained for S1 and S2 compared with no vaccination, respectively. 
CONCLUSIONS: In Thailand, vaccination of females age 12–24 years with a quad-
rivalent (6,11,16,18) HPV vaccine can reduce the incidence of cervical cancer, CIN, 
and genital warts at a cost per QALY ratio within the range typically regarded as 
cost-effective. 
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OBJECTIVES: To estimate the relative cost effectiveness of available contraceptives 
in a paciﬁ c region country (Colombia) from a social perspective. METHODS: A 
Markov model was constructed to simulate costs for 13 contraceptive methods and 
for no contraceptive method over a 10-year period, with a 5% discount rate. Failure 
rates, adverse event rates and resource utilization were derived from literature. Sensi-
tivity analyses were performed on costs and effectiveness rates. RESULTS: The four 
least expensive methods per person month were: copper-T IUD (USD $0.34), vasec-
tomy (USD $1.28), tubal ligation (USD $1.44) and implant (USD $2.19). The cost-
effectiveness analysis of methods to prevent pregnancy showed: the Copper T IUD 
has a ratio of incremental cost-effectiveness (ICER) of USD $5,540 (per month, per 
pregnancy avoided) when it is contrasted with the vasectomy. The Vasectomy is 
dominant compared to tubal ligation, and it presents an ICER of USD $7.371 in 
relation to implant methods. Comparing Copper T with the second most affordable 
reversible method, an ICER of USD $12,033 was obtained. The order of results did 
not change with a discount rate of 0% but were sensitive to the time horizon. CON-
CLUSIONS: Differences in time horizon are inﬂ uential factors that determine the 
dominance of contraceptive methods. It is noteworthy that although the cost of a tubal 
ligation and a vasectomy is the same, the total costs for a vasectomy are lower due 
to reduced complication-related costs. Given that the monthly premium of the com-
pulsory health insurance in Colombia for a woman of childbearing age (19–44 years) 
is USD$22, the value of USD$12,033 or $5540 per month to prevent pregnancy 
through implant or vasectomy is excessive. Therefore, according to the case analysis, 
the Copper T is a cost-effective option for Colombia, including reversible and nonre-
versible methods. 
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OBJECTIVES: Cervical cancer is the second highest incidence of female cancers in 
Malaysia. This can be avoided by Pap smear screening and Human Papillomavirus 
(HPV) vaccination i.e., the bivalent vaccine (BV) and quadrivalent (QV). Three 
programs cost effectiveness (CE) options were compared i.e., screening via Pap smear; 
modeling of HPV vaccination (QV and BV) and combined strategy (screening plus 
vaccination). Scenario based sensitivity analysis using screening population coverage 
(40–80%) and costs of vaccine (RM 100–200/dose) were calculated. METHODS: This 
is a cross sectional study from 2006–2009 and respondents were interviewed from six 
public Gynecology–Oncology hospitals. Methods include experts’ panel discussions 
to estimate treatment costs by severity and direct interviews with respondents using 
costing and quality of life questionnaires. RESULTS: A total of 502 cervical cancer 
patients participated with mean age at 53.3 ± 11.21 years, Malays (44.2%) and 
married for 27.73 ± 12.12 years. Cost/QALYs for Pap smear at base case is RM 
1,214.96/QALYs and RM 1,100.01/QALYs at increased screening coverage. In QV 
only, cost/QALYs saved in base case are at RM 15,662/QALYs and RM 24,203/
QALYs when vaccination price is increased. In BV only; cost/QALYs saved in base 
case is at RM 1359,057/QALYs and RM 2530,017.56/QALYs when vaccination price 
is increased. In QV combined strategy cost/QALYs at base case is RM 4937/QALYs; 
RM 3395/QALYs at best case and RM 7992/QALYs at worst case scenario. In BV 
combined strategy, cost/QALYs at base case is RM 6624/QALYs; RM 4033/QALYs 
at best case and RM 10,543/QALYs at worst case scenario. Incremental cost-
effectiveness ratio (ICER) showed that screening at 70% coverage or higher is highly 
cost effective at RM 946.74 per QALYs saved and this is followed by best case com-
bined strategy with QV at RM 13,000 per QALYs saved. CONCLUSIONS: QV is 
more cost effective than BV. The QV combined strategy is more CE than any method 
except Pap smear screening at high population coverage. 
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OBJECTIVES: Raloxifene (RLX) reduces the risk of vertebral fractures and invasive 
breast cancer (IBC). The National Osteoporosis Foundation (NOF) has recommended 
a threshold for treatment initiation of 10-year major fracture risk of 20%, but given 
RLX’s beneﬁ cial efﬁ cacy on IBC it may be clinically beneﬁ cial and cost-effective to 
treat women with RLX even if they do not meet this threshold. The aim was to identify 
how 5-year IBC risk affects the cost-effectiveness of treating younger postmenopausal 
women who do not meet the 20% absolute fracture risk threshold with RLX com-
pared to no intervention. METHODS: A micro-simulation model populated with data 
speciﬁ c to American women was used to quantify the costs and beneﬁ ts of 5-year 
treatment with RLX from a societal perspective. Possible events were vertebral frac-
ture, IBC, VTE and death. EQ-5D societal health state values were used to estimate 
quality-adjusted life-years (QALYs). The population was selected based on 10-year 
major fracture risk as estimated with FRAX® (5–19.9%) and 5-year IBC risk as 
estimated with Gail risk model (1–5%). RESULTS: The cost per QALY gained ranged 
from US$17,100 to 93,000. RLX was progressively cost-effective with increasing 
fracture risk and IBC risk holding age constant. At lower fracture risk in combination 
with lower IBC risk or when no preventive RLX effect on IBC was assumed, the 
cost-effectiveness of RLX decreased markedly and was not cost-effective given a 
willingness-to-pay of US$50,000. At fracture risk of 15–19.9% RLX was cost-effective 
also in women at lower IBC risk. CONCLUSIONS: RLX is potentially cost-effective 
in young postmenopausal women at elevated IBC risk who do not meet the suggested 
NOF 10-year fracture threshold. This highlights the importance of considering a 
woman’s full risk proﬁ le when deciding which anti-osteoporosis treatment to 
recommend. 
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OBJECTIVES: The study evaluated the cost effectiveness of the bivalent AS04 adju-
vant vaccine in Slovakia and the correlation between vaccine protection duration and 
incremental cost effectiveness of HPV vaccination of 12-year-old girls with bivalent 
AS04 adjuvant vaccine in Slovakia. METHODS: A 1-year cycle Markov model (20—
health state) used age-speciﬁ c data on dysplasia or cervical cancer. A base case analysis 
assumed 98% vaccine efﬁ cacy against HPV—16/18 and 50% vaccination coverage. 
